Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a shorter pill course beat chagas?

NCT ID NCT03672487

Completed Disease control Sponsor: Tulane University School of Public Health and Tropical Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a shorter, lower-dose course of the drug benznidazole works as well as the standard longer treatment for women with Chagas disease. Researchers enrolled 87 women in Argentina who had recently given birth and were infected with the parasite. The goal was to see if the shorter treatment could reduce side effects while still controlling the infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Benznidazole
What this could lead to
If successful, this could offer a shorter, safer treatment option for women with Chagas disease, reducing side effects while still controlling the infection.
What could go wrong
This is a small, completed trial with only 87 participants, and the shorter course may not be as effective as the standard longer treatment. Results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHAGAS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chagas disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHAGAS DISEASE

Contacts and locations

Locations

  • Institute for Clinical Effectiveness and Health Policy

    Buenos Aires, Argentina

  • Tulane School of Public Health and Tropical Medicine

    New Orleans, Louisiana, 70112, United States

  • University of California at San Diego

    San Diego, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.